Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling ...

Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to ...

Illumina has struggled to boost sales and consistently deliver positive earnings. Its Q4 report was largely a disappointment, and management's 2025 guidance came in below Wall Street's ...

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through ...

Illumina is down 15.2% since the beginning of the year, and at $111.06 per share, it is trading 28.4% below its 52-week high of $155.15 from November 2024. Investors who bought $1,000 worth of ...

Illumina ILMN has outperformed the market over the past 20 years by 9.24% on an annualized basis producing an average annual return of 17.63%. Currently, Illumina has a market capitalization of $ ...

Have you looked into how Illumina (ILMN) performed internationally ... Europe contributed $289 million (25.99%) and $260 million (23.24%) to the total revenue, respectively. Of the total revenue ...

The average ILMN price target of $164 implies 25% upside from current levels, with the stock having seen a 5% decline in the last 12 months. See more ILMN analyst ratings Illumina NewsMORE Related ...

Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time ...